Brief: Tonix Pharmaceuticals Announces FDA Ind Clearance For Phase 2 Study Of Tnx-102 Sl
24/11/2025 13:26
Nov 24 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES FDA IND CLEARANCE FOR PHASE 2 STUDY OF TNX-102 SL FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TONIX PHARMACEUTICALS ANNOUNCES FDA IND CLEARANCE FOR PHASE 2 STUDY OF TNX-102 SL FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TONIX PHARMACEUTICALS - PLANS TO INITIATE STUDY ENROLLMENT IN MID-2026 Source text: ID:nGNX6BSmCg Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview